After a year of uncertainties, respite may be around the corner for Aurobindo Pharma, as it recently received a go-ahead from the US Food and Drugs Administration (FDA) for one of its key units and is expecting the same for another. Both the units were under the scanner of FDA since 2011. The latest move would not only clear the logjam for many of Aurobindo’s existing products but would also
Sun Pharma’s stock closed 2.76 per cent up on a stellar performance for the quarter and year ended March. Taro, its Israel-based subsidiary, clocked in a sales growth of 35 per cent
Four Indian drug makers — Dr Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd and Aurobindo Pharma Ltd — have received approval from the US
The Spices Board of India has been undertaking programmes throughout the country especially in the states of Gujarat, Rajasthan, Madhya Pradesh, and Andhra Pradesh to effectively link the spices
Ranbaxy Laboratories will have to perpetually be on its toes, as the ‘consent decree’ it signed with the US Food and Drug Administration (USFDA) last month stipulates financial
Ranbaxy's September quarter results were below Street estimates. Its bottom line was hit harder due to losses on foreign currency loans (Rs 251 crore) and mark-to-market loss on derivative
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise